Table 2.

Treatments used adjunctively with DEX implant for complications of RVO in treatment-naïve patients

Treatments used in addition to DEX implant	Treatment-naïve patients
	(N = 39)
Any treatment, n (%)	27 (69.2)
Intravitreal injection
Anti-VEGF, n (%)	23 (59.0)
Ranibizumab, n (%)	16 (41.0)
Bevacizumab, n (%)	9 (23.1)
Mean number of ranibizumab or bevacizumab injections in patients receiving anti-VEGF	3.2
Range	1–6
Laser photocoagulation
Focal, n (%)	11 (28.2)
Panretinal, n (%)	1 (2.6)

DEX implant dexamethasone intravitreal implant, RVO retinal vein occlusion, VEGF vascular endothelial growth factor